VOYA Investment Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

VOYA Investment Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,841	Closed	-$61K	–	2912
2022 Q1	$61K	Hold	12,841	–	–	﹤0.01%	2574
2021 Q4	$47K	Sell	12,841 -1,514	-11%	-$8.08K	﹤0.01%	2747
2021 Q3	$115K	Hold	14,355	–	–	﹤0.01%	2710
2021 Q2	$163K	Buy	+14,355	New	+$144K	﹤0.01%	2663
2015 Q2	–	Sell	-183	Closed	-$94K	–	2665
2015 Q1	$94K	Hold	183	–	–	﹤0.01%	2533
2014 Q4	$98K	Hold	183	–	–	﹤0.01%	2574
2014 Q3	$274K	Hold	183	–	–	﹤0.01%	2324
2014 Q2	$250K	Hold	183	–	–	﹤0.01%	2445
2014 Q1	$254K	Hold	183	–	–	﹤0.01%	2415
2013 Q4	$182K	Hold	183	–	–	﹤0.01%	2504
2013 Q3	$190K	Hold	183	–	–	﹤0.01%	2501
2013 Q2	$200K	Buy	+183	New	+$204K	﹤0.01%	2493

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

VOYA Investment Management's VIRX Position: Q2 2022 in Review

VOYA Investment Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2022, closing a stake of 12,841 shares — an estimated $61K sold.

VOYA Investment Management first reported a position in VIRX in Q2 2013 and held it in 12 quarters. The position peaked at $274K in Q3 2014. 63 funds tracked by Wall St. Rank hold VIRX as of Q2 2022.

VOYA Investment Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
VOYA Investment Management sold 12,841 Viracta Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $61K.
VOYA Investment Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
VOYA Investment Management's Viracta Therapeutics, Inc. Common Stock position peaked at $274K in Q3 2014.
63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2022.

Based on VOYA Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.